

HENRY A. WAXMAN, CALIFORNIA
EDWARD J. MARKEY, MASSACHUSETTS
RICK BOUCHER, VIRGINIA
EDOLPHUS TOWNS, NEW YORK
FRANK PALLONE, Jr., NEW JERSEY
BART GORDON, TENNESSEE
BOBBY L. RUSH, ILLINOIS
ANNA G. ESHOO, CALIFORNIA
BART STUPAK, MICHIGAN
ELIOT L. ENGEL, NEW YORK
ALBERT R. WYNN, MARYLAND
GENE GREEN, TEXAS
DIANA DEGETTE, COLORADO
VICE CHAIRMAN
LOIS CAPPS, CALIFORNIA
MIKE DOYLE, PENNSYLVANIA
JANE HARMAN, CALIFORNIA
TOM ALLEN, MAINE
JAN SCHAKOWSKY, ILLINOIS
HILDA L. SOLIS, CALIFORNIA
CHARLES A. GONZALEZ, TEXAS
JAY INSLEE, WASHINGTON
TAMMY BALDWIN, WISCONSIN
MIKE ROSS, ARKANSAS
DARLENE HOOLEY, OREGON
ANTHONY D. WEINER, NEW YORK
JIM MATHESON, UTAH
G.K. BUTTERFIELD, NORTH CAROLINA
CHARLIE MELANCON, LOUISIANA
JOHN BARROW, GEORGIA
BARON P. HILL, INDIANA

ONE HUNDRED TENTH CONGRESS

U.S. House of Representatives
Committee on Energy and Commerce
Washington, DC 20515-6115

JOHN D. DINGELL, MICHIGAN
CHAIRMAN

April 4, 2007

JOE BARTON, TEXAS
RANKING MEMBER
RALPH M. HALL, TEXAS
J. DENNIS HASTERT, ILLINOIS
FRED UPTON, MICHIGAN
CLIFF STEARNS, FLORIDA
NATHAN DEAL, GEORGIA
ED WHITFIELD, KENTUCKY
BARBARA CUBIN, WYOMING
JOHN SHIMKUS, ILLINOIS
HEATHER WILSON, NEW MEXICO
JOHN B. SHADEGG, ARIZONA
CHARLES W. "CHIP" PICKERING, MISSISSIPPI
VITO FOSSELLA, NEW YORK
STEVE BUYER, INDIANA
GEORGE RADANOVICH, CALIFORNIA
JOSEPH R. PITTS, PENNSYLVANIA
MARY BONO, CALIFORNIA
GREG WALDEN, OREGON
LEE TERRY, NEBRASKA
MIKE FERGUSON, NEW JERSEY
MIKE ROGERS, MICHIGAN
SUE MYRICK, NORTH CAROLINA
JOHN SULLIVAN, OKLAHOMA
TIM MURPHY, PENNSYLVANIA
MICHAEL C. BURGESS, TEXAS
MARSHA BLACKBURN, TENNESSEE

DENNIS B. FITZGIBBONS, CHIEF OF STAFF
GREGG A. ROTHSCHILD, CHIEF COUNSEL

The Honorable Andrew C. von Eschenbach, M.D.
Commissioner
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Dear Dr. von Eschenbach:

The House and Senate recently received the recommendations of the Food and Drug Administration (FDA) and interested stakeholders with regard to the reauthorization of the Prescription Drug User Fee Act (PDUFA). Given the importance of this program, we will work to ensure reauthorization of this valuable program, which is set to expire on September 30, 2007.

As the Committee on Energy and Commerce conducts the PDUFA reauthorization process, we believe it is important that the Congress understand the specific time frame in which work must be completed in order to avoid any personnel disruptions in this program.

We request that you provide to us a date certain by which the FDA would need to issue a reduction-in-force (RIF) notice under part 351 of title 5, Code of Federal Regulations, to those affected employees should it appear that PDUFA reauthorization will not be completed by its expiration under current law.

Thank you for your attention to this matter. We look forward to working with you and other stakeholders as we move forward in the reauthorization of PDUFA. We ask that you please respond to this inquiry by no later than Tuesday, April 17, 2007.

The Honorable Andrew C. von Eschenbach
Page 2

If you have any questions regarding this request, please have your staff contact John Ford with the Committee on Energy and Commerce staff at (202) 226-2424.

Sincerely,

A handwritten signature in blue ink, appearing to read "John D. Dingell", written over a horizontal line.

John D. Dingell
Chairman

A handwritten signature in blue ink, appearing to read "Frank Pallone, Jr.", written over a horizontal line.

Frank J. Pallone, Jr.
Chairman
Subcommittee on Health

cc: The Honorable Joe Barton, Ranking Member
Committee on Energy and Commerce

The Honorable Nathan Deal, Ranking Member
Subcommittee on Health